Quality of Life of Japanese Dysmenorrhea/Heavy Menstrual Bleeding Patients Treated with Levonorgestrel Intrauterine Delivery System in a Real-World Setting

Mikio Momoeda, Shigeo Akira, Tasuku Harada, Jo Kitawaki, Nagamasa Maeda, Ikuko Ota, Keisuke Yoshihara, Noriko Takahashi, Mikio Momoeda, Shigeo Akira, Tasuku Harada, Jo Kitawaki, Nagamasa Maeda, Ikuko Ota, Keisuke Yoshihara, Noriko Takahashi

Abstract

Introduction: The present study collected 1-year follow-up patient-reported outcome data from Japanese women with dysmenorrhea and/or heavy menstrual bleeding (HMB) who underwent insertion of the levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg. We aimed to evaluate the quality of life (QOL) of Japanese women over the course of the investigational period.

Methods: This was a multicenter, non-interventional, prospective, single-cohort, post-marketing surveillance study (J-MIRAI). The primary outcome was the median change in the Menstrual Distress Questionnaire (MDQ) and Menorrhagia Multi-Attribute Scale (MMAS) scores from baseline to 3 and 12 months after LNG-IUS insertion, with decreasing and increasing scores, respectively, indicating improvement. The secondary outcomes were the statistical relationships between the MDQ and menstrual pain (measured by a visual analog scale, VAS), and between the MMAS and pictorial blood loss assessment chart (PBAC) scores by regression analysis.

Results: In total, 593 patients were evaluated; 376, 467, and 250 patients were diagnosed with dysmenorrhea, HMB, or both, respectively. The median MDQ score decreased significantly at 3 and 12 months after LNG-IUS insertion in both the premenstrual and menstrual periods (both p < 0.001 vs baseline), and the median MMAS score showed a similar improvement during the menstrual period. Changes in median MDQ and MMAS scores were observed regardless of patient background. Correlations between MDQ and menstrual pain (VAS) and between MMAS and PBAC scores were found (estimated regression coefficients 0.29 and - 0.15, respectively).

Conclusion: The LNG-IUS contributed to improvements in the QOL of patients with dysmenorrhea, HMB, and both, regardless of patient background characteristics.

Trial registration: Registered at ClinicalTrials.gov (NCT02475356) on 18 June 2015.

Keywords: Dysmenorrhea; Heavy menstrual bleeding; Japan; Levonorgestrel-releasing intrauterine system; Menorrhagia multi-attribute scale (MMAS); Menstrual distress questionnaire (MDQ); Patient-reported outcome; Quality of life.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Change in MDQ total scores during the premenstrual period (a) and menstrual period (b). ***p < 0.001 (Wilcoxon signed-rank test vs baseline median value). Data are plotted with missing value completion. MDQ Menstrual Distress Questionnaire
Fig. 2
Fig. 2
Change in the domain scores of the MDQ during the premenstrual period (a) and menstrual period (b). *p < 0.05, ** p < 0.01, ***p < 0.001 (Wilcoxon signed-rank test vs baseline median value). Data are plotted with missing value completion. MDQ Menstrual Distress Questionnaire
Fig. 3
Fig. 3
Change in the MMAS total score during the menstrual period. ***p < 0.001 (Wilcoxon signed-rank test vs baseline median value). Data are plotted with missing value completion. MMAS Menorrhagia Multi-Attribute Scale
Fig. 4
Fig. 4
Change in the domain scores of the MMAS during the menstrual period. ***p < 0.001 (Wilcoxon signed-rank test vs baseline median value). Data are plotted with missing value completion. MMAS Menorrhagia Multi-Attribute Scale
Fig. 5
Fig. 5
The log-normal regression analysis for the correlation between MDQ and menstrual pain (VAS) (a) and MMAS and PBAC (b). MDQ Menstrual Distress Questionnaire, MMAS Menorrhagia Multi-Attribute Scale, PBAC pictorial blood loss assessment chart, VAS visual analog scale

References

    1. Sriprasert I, Pakrashi T, Kimble T, Archer DF. Heavy menstrual bleeding diagnosis and medical management. Contracept Reprod Med. 2017;2:20. doi: 10.1186/s40834-017-0047-4.
    1. Armour M, Parry K, Manohar N, et al. The prevalence and academic impact of dysmenorrhea in 21,573 young women: a systematic review and meta-analysis. J Womens Health (Larchmt) 2019;28:1161–1171. doi: 10.1089/jwh.2018.7615.
    1. Ju H, Jones M, Mishra G. The prevalence and risk factors of dysmenorrhea. Epidemiol Rev. 2014;36:104–113. doi: 10.1093/epirev/mxt009.
    1. Fraser IS, Mansour D, Breymann C, Hoffman C, Mezzacasa A, Petraglia F. Prevalence of heavy menstrual bleeding and experiences of affected women in a European patient survey. Int J Gynaecol Obstet. 2015;128:196–200. doi: 10.1016/j.ijgo.2014.09.027.
    1. Tanaka E, Momoeda M, Osuga Y, et al. Burden of menstrual symptoms in Japanese women: results from a survey-based study. J Med Econ. 2013;16:1255–1266. doi: 10.3111/13696998.2013.830974.
    1. Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical review. Hum Reprod Update. 2015;21:762–778. doi: 10.1093/humupd/dmv039.
    1. Nagy H, Khan MAB. Dysmenorrhea. StatPearls. 2021. . Accessed 10 Mar 2021.
    1. Osuga Y, Hayashi K, Kobayashi Y, et al. Dysmenorrhea in Japanese women. Int J Gynaecol Obstet. 2005;88:82–83. doi: 10.1016/j.ijgo.2004.09.004.
    1. Kawaguchi R, Matsumoto K, Ishikawa T, et al. Guideline for gynecological practice in Japan: Japan Society of Obstetrics and Gynecology and Japan Association of Obstetricians and Gynecologists 2020 edition. J Obstet Gynaecol Res. 2021;47:5–25. doi: 10.1111/jog.14487.
    1. Japan Society of Obstetrics and Gynecology . Obstetrics and gynecology glossary. 4. Tokyo: Kyorinsya; 2018.
    1. Davies J, Kadir RA. Heavy menstrual bleeding: an update on management. Thromb Res. 2017;151:S70–S77. doi: 10.1016/S0049-3848(17)30072-5.
    1. Mansour D, Hofmann A, Gemzell-Danielsson K. A review of clinical guidelines on the management of iron deficiency and iron-deficiency anemia in women with heavy menstrual bleeding. Adv Ther. 2021;38:201–225. doi: 10.1007/s12325-020-01564-y.
    1. National Institute for Health and Care Excellence (NICE) guideline. Heavy menstrual bleeding: assessment and management. 2018. . Accessed 10 Mar 2021.
    1. Laksham KB, Selvaraj R, Kar SS. Menstrual disorders and quality of life of women in an urban area of Puducherry: a community-based cross-sectional study. J Family Med Prim Care. 2019;8:137–140. doi: 10.4103/jfmpc.jfmpc_209_18.
    1. Engstrom JL, Rose R, Brill AI, Polhill KM, Lukanich CM, Fritz L. Midwifery care of the woman with menorrhagia. J Nurse Midwifery. 1999;44:89–105. doi: 10.1016/S0091-2182(99)00029-4.
    1. Unsal A, Ayranci U, Tozun M, Arslan G, Calik E. Prevalence of dysmenorrhea and its effect on quality of life among a group of female university students. Ups J Med Sci. 2010;115:138–145. doi: 10.3109/03009730903457218.
    1. Rodrigues AC, Gala S, Neves Â, et al. Dismenorreia em adolescentes e jovens adultas: prevalência, factores associados e limitações na vida diária [Dysmenorrhea in adolescents and young adults: prevalence, related factors and limitations in daily living] Acta Med Port. 2011;24:383–388.
    1. Luukkainen T, Lähteenmäki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med. 1990;22:85–90. doi: 10.3109/07853899009147248.
    1. Costescu DJ. Levonorgestrel-releasing intrauterine systems for long-acting contraception: current perspectives, safety, and patient counseling. Int J Womens Health. 2016;8:589–598. doi: 10.2147/IJWH.S99705.
    1. Bayer HealthCare Pharmaceuticals. Mirena Highlights of Prescribing Information. . Accessed 10 Mar 2021.
    1. Endrikat J, Vilos G, Muysers C, Fortier M, Solomayer E, Lukkari-Lax E. The levonorgestrel-releasing intrauterine system provides a reliable, long-term treatment option for women with idiopathic menorrhagia. Arch Gynecol Obstet. 2012;285:117–121. doi: 10.1007/s00404-011-1902-1.
    1. Ministry of Health, Labour and Welfare. The Japanese guideline for Good Post-marketing Study Practice. . Accessed 10 Mar 2021. (Japanese).
    1. Akiyama A, Kayasima K. The Japanese version of Menstrual Distress questionnaire. Nurs Psychol. 1979;5:272–277.
    1. Momoeda M, Tanaka E, Kawaguchi M. Development of the Japanese version of the Menorrhagia Multi-Attribute Scale (MMAS): translation and linguistic validation. Sanka Fujinka [Obstetrics and Gynecology] 2015;82:1299–1305.
    1. Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA. Studies with pain rating scales. Ann Rheum Dis. 1978;37:378–381. doi: 10.1136/ard.37.4.378.
    1. Scott J, Huskisson EC. Vertical or horizontal visual analogue scales. Ann Rheum Dis. 1979;38:560. doi: 10.1136/ard.38.6.560.
    1. McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med. 1988;18:1007–1019. doi: 10.1017/S0033291700009934.
    1. Gaston-Johansson F. Measurement of pain: the psychometric properties of the Pain-O-Meter, a simple, inexpensive pain assessment tool that could change health care practices. J Pain Symptom Manage. 1996;12:172–181. doi: 10.1016/0885-3924(96)00128-5.
    1. Bodian CA, Freedman G, Hossain S, Eisenkraft JB, Beilin Y. The visual analog scale for pain: clinical significance in postoperative patients. Anesthesiology. 2001;95:1356–1361. doi: 10.1097/00000542-200112000-00013.
    1. Halimeh S, Rott H, Kappert G. PBAC score: an easy-to-use tool to predict coagulation disorders in women with idiopathic heavy menstrual bleeding. Haemophilia. 2016;22:e217–e220. doi: 10.1111/hae.12886.
    1. Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990;97:734–739. doi: 10.1111/j.1471-0528.1990.tb16249.x.
    1. Ikeda S, Shiroiwa T, Igarashi A, et al. Developing a Japanese version of the EQ-5D-5L value set. J Natl Inst Public Health. 2015;64:47–55.
    1. Bayer. Mirena intrauterine delivery system 52 mg, . Accessed 10 Mar 2021. (Japanese)
    1. Momoeda M, Akiyama S, Tanaka K, Suzukamo Y. Quality of life in Japanese patients with dysmenorrhea treated with ethinylestradiol 20 μg/drospirenone 3 mg in a real-world setting: An observational study. Int J Womens Health. 2020;12:327–338. doi: 10.2147/IJWH.S238460.
    1. Xu L, Lee BS, Asif S, Kraemer P, Inki P. Satisfaction and health-related quality of life in women with heavy menstrual bleeding; results from a non-interventional trial of the levonorgestrel-releasing intrauterine system or conventional medical therapy. Int J Womens Health. 2014;6:547–554.
    1. Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med. 2013;368:128–137. doi: 10.1056/NEJMoa1204724.
    1. Lethaby A, Hussain M, Rishworth JR, Rees MC. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2015; CD002126. Update in: Cochrane Database Syst Rev. 2020; 6:CD002126.
    1. Wildemeersch D, Schacht E, Wildemeersch P. Treatment of primary and secondary dysmenorrhea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care. 2001;6:192–198. doi: 10.1080/ejc.6.4.192.198.
    1. Costanzi F, De Marco MP, Colombrino C, et al. The treatment with Levonorgestrel Releasing Intrauterine System (LNG-IUS) in patients affected by menometrorrhagia, dysmenorrhea and adenomimyois: clinical and ultrasonographic reports. Eur Rev Med Pharmacol Sci. 2021;25:3432–3439.
    1. Yoo HJ, Lee MA, Ko YB, Yang JB, Kang BH, Lee KH. The efficacy of the levonorgestrel-releasing intrauterine system in perimenopausal women with menorrhagia or dysmenorrhea. Arch Gynecol Obstet. 2012;285:161–166. doi: 10.1007/s00404-011-1937-3.
    1. Beelen P, van den Brink MJ, Herman MC, et al. Levonorgestrel-releasing intrauterine system versus endometrial ablation for heavy menstrual bleeding. Am J Obstet Gynecol. 2021;224:187.e1–187.e10. doi: 10.1016/j.ajog.2020.08.016.
    1. Lu M, Yang X. Levonorgestrel-releasing intrauterine system for treatment of heavy menstrual bleeding in adolescents with Glanzmann's Thrombasthenia: illustrated case series. BMC Womens Health. 2018;18:45. doi: 10.1186/s12905-018-0533-0.

Source: PubMed

3
订阅